ImmunoPrecise Antibodies Ltd. (IPA)
|Net Income (ttm)||n/a|
|Trading Day||January 22|
|Day's Range||14.85 - 15.80|
|52-Week Range||13.40 - 16.73|
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today ...
VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("Company" or "IPA") (TSXV: IPA) (Nasdaq: IPA), a leader in full-service, therapeutic antibody discovery and developm...
VICTORIA, BC, Nov. 3, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discover...
Developing Antibodies for Covid-19
Sep.28 -- Jennifer Bath, chief executive officer at Immunoprecise Antibodies Ltd., discusses the company's potentially groundbreaking Covid-19 antibody treatment on "Bloomberg Technology.
ImmunoPrecise Antibodies engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; t... [Read more...]
|IPO Date |
Jan 3, 2017
|Stock Exchange |
|Ticker Symbol |
In 2020, IPA's revenue was 14.06 million, an increase of 28.66% compared to the previous year's 10.93 million. Losses were -4.95 million, -35.05% less than in 2019.